Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Transcriptional enhancer factor TEAD and Yes-associated protein 1 (TEAD-YAP1) complex is the primary transcriptional effector of the Hippo signaling pathway, which plays a critical role in regulating organ size, cell proliferation, and tissue homeostasis [PMID: 29109595]. YAP1 serves as a transcriptional co-activator that lacks its own DNA-binding domain and must physically associate with TEAD family transcription factors (TEAD1-4) to initiate the transcription of genes involved in cell survival and the epithelial-mesenchymal transition [PMID: 18568018]. In many human cancers, the Hippo pathway is disrupted by mutations in upstream tumor suppressors such as NF2 or LATS1/2, leading to the constitutive activation and nuclear localization of YAP1 [PMID: 25298330]. This hyperactivation drives tumor growth, metastasis, and resistance to conventional therapies, making the TEAD-YAP1 interaction a high-value target for drug development. Current therapeutic strategies involve small molecules that disrupt this protein-protein interaction, either by binding to a conserved hydrophobic palmitoylation pocket within the TEAD protein or by directly blocking the YAP1-binding interface [PMID: 33031744]. Clinical candidates like VT3989 and IK-930 are currently being investigated for the treatment of NF2-deficient mesothelioma and other Hippo-pathway-altered solid tumors [ClinicalTrials.gov NCT04665206]. However, drug development faces challenges regarding potential toxicities, particularly in the kidney and during wound healing, where the Hippo pathway maintains physiological function.
Small molecule inhibition of the protein-protein interaction between TEAD transcription factors and the YAP1 co-activator, typically by binding to the conserved TEAD palmitoylation pocket to allosterically disrupt binding or by directly blocking the YAP-binding interface.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcriptional enhancer factor TEAD and Yes-associated protein 1 complex (TEAD-YAP1).